Physician profile
Benjamin Rodriguez
NPI 1780650440
$68,977.14
in general payments reported to CMS, 2019-2025
24 companies · $65K in 2025
The $65K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $333 · 2023: $677 · 2024: $3,089 · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $3,233 · Travel and Lodging: $3,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,247.50 |
| Food and Beverage | $3,233.09 |
| Travel and Lodging | $3,163.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $66,107.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $781.99 | 2022-2025 | Mavyret, Viberzi, Linzess |
| Genzyme Corporation | $279.00 | 2022-2025 | |
| Gilead Sciences, INC. | $250.57 | 2024-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $248.25 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $203.20 | 2022-2025 | Simponi, Stelara, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $202.83 | 2023-2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.88 | 2023-2024 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $161.19 | 2022-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $86.97 | 2023-2025 | Vowst, Zenpep |
| Phathom Pharmaceuticals, INC. | $80.94 | 2024-2025 | Voquezna |
| Celgene Corporation | $46.78 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $41.27 | 2024-2025 | Ibsrela |
| Amgen INC. | $40.83 | 2025 | Uplizna |
| Braintree Laboratories, INC. | $34.92 | 2022-2024 | Suflave, Sutab |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.27 | 2024 | Omvoh |
| Fujifilm Healthcare Americas Corporation | $29.61 | 2023 | Fujifilm |
| Pfizer INC. | $29.43 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $28.83 | 2023 | |
| Fresenius Kabi USA, LLC | $22.23 | 2024 | Idacio |
| Axonics, INC. | $19.50 | 2024 | Axonics |
| Ironwood Pharmaceuticals, INC | $18.40 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.25 | 2025 | Iqirvo |
| Shield Therapeutics INC | $16.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.